477 related articles for article (PubMed ID: 25076063)
21. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus reactivation associated with anti-neoplastic therapy.
Yeo W; Chan HL
J Gastroenterol Hepatol; 2013 Jan; 28(1):31-7. PubMed ID: 23020594
[TBL] [Abstract][Full Text] [Related]
23. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients.
Matsue K; Aoki T; Odawara J; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuch M
Eur J Haematol; 2009 Oct; 83(4):357-64. PubMed ID: 19508685
[TBL] [Abstract][Full Text] [Related]
24. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
26. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
Knöll A; Boehm S; Hahn J; Holler E; Jilg W
J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.
Salpini R; Colagrossi L; Bellocchi MC; Surdo M; Becker C; Alteri C; Aragri M; Ricciardi A; Armenia D; Pollicita M; Di Santo F; Carioti L; Louzoun Y; Mastroianni CM; Lichtner M; Paoloni M; Esposito M; D'Amore C; Marrone A; Marignani M; Sarrecchia C; Sarmati L; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
Hepatology; 2015 Mar; 61(3):823-33. PubMed ID: 25418031
[TBL] [Abstract][Full Text] [Related]
28. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
Tamori A; Hino M; Kawamura E; Fujii H; Uchida-Kobayashi S; Morikawa H; Nakamae H; Enomoto M; Murakami Y; Kawada N
J Gastroenterol Hepatol; 2014 Sep; 29(9):1715-21. PubMed ID: 24730465
[TBL] [Abstract][Full Text] [Related]
29. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
[TBL] [Abstract][Full Text] [Related]
30. [A case of the usage of entecavir to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patient].
Muraoka T; Taira N; Shien T; Doihara H; Takaki A; Miyoshi S
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1861-4. PubMed ID: 22083198
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
32. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
Yağci M; Ozkurt ZN; Yeğin ZA; Aki Z; Sucak GT; Haznedar R
Hematology; 2010 Aug; 15(4):240-4. PubMed ID: 20670484
[TBL] [Abstract][Full Text] [Related]
33. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
34. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy.
Keam B; Lee JH; Im SA; Yoon JH
J Natl Compr Canc Netw; 2011 May; 9(5):465-77. PubMed ID: 21550967
[TBL] [Abstract][Full Text] [Related]
35. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Rossi G; Pelizzari A; Motta M; Puoti M
Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
37. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
38. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.
Paul S; Dickstein A; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
Hepatology; 2017 Aug; 66(2):379-388. PubMed ID: 28128861
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
40. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]